疫苗接种提高复发儿童急性淋巴细胞白血病中CD19CAR基因修饰T细胞的持续性
一项多中心I/II期研究评估供者CD19CAR转导的EBV特异性T细胞(EBV CTL)治疗儿童急性淋巴细胞白血病(ALL),11例患者中未观察到细胞因子释放综合征(CRS)、神经毒性或移植物抗宿主病(GVHD);疫苗接种增强了CD19CAR CTL的持续性,中位持续性无疫苗接种为0天(范围0-28),疫苗接种为56天(范围0-221),P=0.06。
要点
- 供者CD19CAR转导的EBV CTL在儿童ALL中未引起CRS、神经毒性或GVHD。
- 疫苗接种增强CD19CAR CTL持续性:中位持续性无疫苗0天 vs 疫苗56天,P=0.06。
- 11例中10例在12个月中位随访时复发,1例持续完全缓解3年。
核心结论
- 本研究证明多中心CAR T细胞治疗研究的可行性,以及疫苗接种增强持续性的潜力。
研究设计与样本
- 多中心I/II期研究,纳入儿童急性淋巴细胞白血病(ALL)患者,在首次干细胞移植(SCT)后分子复发(>5×10-4)时预防性治疗,或第二次SCT后预防性治疗。
- 供者EBV特异性T细胞(EBV CTL)转导第一代CD19CAR,依赖内源性T细胞受体增殖。
- 共治疗11例患者;初始队列显示扩增/持续性差,故研究EBV定向疫苗接种以增强扩增/持续性。
主要发现
- 未观察到细胞因子释放综合征(CRS)、神经毒性或移植物抗宿主病(GVHD)。
- 1个月时,5例完全缓解(CR)(4例持续,1例新发),1例部分缓解(PR),3例疾病稳定,3例无反应。
- 中位随访12个月,11例中10例复发,2例带病生存,1例完全缓解生存3年。
- CD19CAR CTL扩增差,但疫苗接种增强持续性:无疫苗接种中位持续性0天(范围0-28),疫苗接种中位持续性56天(范围0-221),P=0.06。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Trials with second generation CD19 chimeric antigen receptors (CAR) T-cells report unprecedented responses but are associated with risk of cytokine release syndrome (CRS). Instead, we studied the use of donor Epstein-Barr virus-specific T-cells (EBV CTL) transduced with a first generation CD19CAR, relying on the endogenous T-cell receptor for proliferation. We conducted a multi-center phase I/II study of donor CD19CAR transduced EBV CTL in pediatric acute lymphoblastic leukaemia (ALL). Patients were eligible pre-emptively if they developed molecular relapse (>5 × 10-4) post first stem cell transplant (SCT), or prophylactically post second SCT. An initial cohort showed poor expansion/persistence. We therefore investigated EBV-directed vaccination to enhance expansion/persistence. Eleven patients were treated. No CRS, neurotoxicity or graft versus host disease (GVHD) was observed. At 1 month, 5 patients were in CR (4 continuing, 1 de novo), 1 PR, 3 had stable disease and 3 no response. At a median follow-up of 12 months, 10 of 11 have relapsed, 2 are alive with disease and 1 alive in CR 3 years. Although CD19CAR CTL expansion was poor, persistence was enhanced by vaccination. Median persistence was 0 (range: 0-28) days without vaccination compared to 56 (range: 0-221) days with vaccination (P=0.06). This study demonstrates the feasibility of multi-center studies of CAR T cell therapy and the potential for enhancing persistence with vaccination.
引用
- Rossig C, Pule M, Altvater B, et al. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia. 2017. PMID: 28126984. doi:10.1038/leu.2017.39
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。